9.29
0.83 (9.81%)
| Penutupan Terdahulu | 8.46 |
| Buka | 8.45 |
| Jumlah Dagangan | 1,088,242 |
| Purata Dagangan (3B) | 1,158,631 |
| Modal Pasaran | 787,750,208 |
| Harga / Buku (P/B) | 7.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Dec 2024 |
| EPS Cair (TTM) | -0.520 |
| Nisbah Semasa (MRQ) | 12.04 |
| Aliran Tunai Operasi (OCF TTM) | -30.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.06 M |
| Pulangan Atas Aset (ROA TTM) | -20.43% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Anavex Life Sciences Corp. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.38 |
|
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.05% |
| % Dimiliki oleh Institusi | 32.03% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 46.00 (EF Hutton, 395.16%) | Beli |
| 46.00 (D. Boral Capital, 395.16%) | Beli | |
| Median | 46.00 (395.16%) | |
| Rendah | 42.00 (HC Wainwright & Co., 352.10%) | Beli |
| Purata | 44.67 (380.84%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 9.56 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Dec 2024 | 42.00 (352.10%) | Beli | 10.87 |
| 27 Nov 2024 | 40.00 (330.57%) | Beli | 9.03 | |
| D. Boral Capital | 23 Dec 2024 | 46.00 (395.16%) | Beli | 11.18 |
| 26 Nov 2024 | 46.00 (395.16%) | Beli | 9.04 | |
| EF Hutton | 31 Oct 2024 | 46.00 (395.16%) | Beli | 6.62 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |